CARL
Carlsmed, Inc. Common StockCARL
CARL
About: Carlsmed Inc is a commercial-stage medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and beyond. It is focused on becoming the standard of care for spine fusion surgery. The aprevo Technology Platform consists of AI-enabled software solutions, and interbody implants that it custom design for each patient's unique pathology and vertebral bone topography, and single-use surgical instruments. The Company designs, manufactures, and markets aprevo, a comprehensive technology platform for spine fusion surgery procedures.
–
Funds holding %
of 7,327 funds
–
Analysts bullish %
Fund manager confidence
Research analyst outlook
We haven’t received any recent analyst ratings for CARL.
Financial journalist opinion
Based on 8 articles about CARL published over the past 30 days
Neutral
GlobeNewsWire
10 hours ago
Carlsmed's aprevo® Personalized Interbody Implants Receive CMS New Technology Add-On Payment (NTAP) for Cervical Fusion Procedures
CARLSBAD, Calif., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (“Carlsmed”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced that in the Hospital Inpatient Prospective Payment Systems Final Rule (IPPS) for fiscal year (FY) 2026, the Centers for Medicare & Medicaid Services (CMS) granted New Technology Add-On Payment (NTAP) reimbursement to cervical fusion procedures using the company's aprevo® personalized interbody implants.
Neutral
24/7 Wall Street
10 hours ago
These 4 Stocks Are Seeing Huge Insider Buying
Insider buying has been slow this past month, as buy windows close as the new earnings-reporting season gets underway.
Neutral
GlobeNewsWire
4 days ago
Carlsmed's aprevo® Powers First Personalized Cervical Spine Surgery
CARLSBAD, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced the successful completion of the first aprevo® cervical procedure on July 14, 2025 by Joseph Osorio, MD, PhD, Chief of Spine Surgery in the Department of Neurological Surgery at UC San Diego (UCSD) Health in San Diego, CA.
Negative
Seeking Alpha
1 week ago
Carlsmed: Spine Play Does Not Have My Backing Yet
Carlsmed's IPO debut is steady, with shares trading near the offering price, reflecting investor caution on its one-product, loss-making business model. Despite doubling sales and manageable cash burn, Carlsmed's valuation at 5–6x annualized sales appears reasonable given rapid revenue growth and a strong cash position. Key risks include heavy reliance on a single product, regulatory uncertainties, and competitive threats, making the investment thesis a high-risk, high-reward proposition.
Neutral
Business Wire
1 week ago
Carlsmed Announces Pricing of Initial Public Offering
CARLSBAD, Calif.--(BUSINESS WIRE)--Carlsmed, Inc. (“Carlsmed”), a commercial-stage medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced the pricing of its initial public offering of 6,700,000 shares of common stock at an initial price to the public of $15.00 per share. The shares are expected to begin trading on The Nasdaq Global Select Market under the ticker symbol “CARL” on July 23, 2025. The offering is expected to close on July 24, 2025, su.
Neutral
Business Wire
1 week ago
Carlsmed Announces Launch of Initial Public Offering
CARLSBAD, Calif.--(BUSINESS WIRE)--Carlsmed, Inc. (“Carlsmed”), a commercial-stage medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced the launch of its initial public offering of 6,700,000 shares of common stock. In addition, the underwriters will have a 30-day option to purchase up to 1,005,000 additional shares of common stock from Carlsmed at the initial public offering price, less underwriting discounts and commissions. The initial public.
Positive
Seeking Alpha
1 week ago
U.S. IPO Weekly Recap: Mining Companies Lead The Calendar As More Sizable IPOs Submit Initial Filings
Six issuers debuted in the US this past week, led by two mining companies. Three blank check companies also went public, and a handful of notable IPO candidates joined the pipeline. Four sizable IPOs are currently scheduled to list in the week ahead.
Neutral
Business Wire
2 weeks ago
Carlsmed Announces Launch of Initial Public Offering
CARLSBAD, Calif.--(BUSINESS WIRE)--Carlsmed, Inc. (“Carlsmed”), a commercial-stage medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced the launch of its initial public offering of 6,700,000 shares of common stock. In addition, the underwriters will have a 30-day option to purchase up to 1,005,000 additional shares of common stock from Carlsmed at the initial public offering price, less underwriting discounts and commissions. The initial public.
Neutral
Seeking Alpha
1 month ago
Carlsmed Files For IPO On High Growth And High Operating Losses
Carlsmed, Inc. has filed to raise $100 million in a U.S. IPO, but the final figure may differ. The company targets a large, but moderately growing spinal surgery market, with expansion plans in cervical spine and international markets. Sales and marketing efficiency is improving, yet the firm faces risks from high losses, reliance on a single product, and supply chain vulnerabilities.
Charts implemented using Lightweight Charts™